Robeco Institutional Asset Management
IMVT icon

Robeco Institutional Asset Management’s Immunovant IMVT Stock Holding History

Robeco Institutional Asset Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-7,680
Closed -$146K – 1037
2023
Q2 		$146K Hold
7,680
– – ﹤0.01% 960
2023
Q1 		$119K Buy
+7,680
New +$133K ﹤0.01% 970

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Robeco Institutional Asset Management's IMVT Position: Q3 2023 in Review

Robeco Institutional Asset Management sold out of Immunovant (IMVT) in Q3 2023, closing a stake of 7,680 shares — an estimated $146K sold.

Robeco Institutional Asset Management first reported a position in IMVT in Q1 2023 and held it in 2 quarters. The position peaked at $146K in Q2 2023. 181 funds tracked by Wall St. Rank hold IMVT as of Q3 2023.

  • Robeco Institutional Asset Management reported no remaining Immunovant position as of Q3 2023 after selling out during the quarter.
  • Robeco Institutional Asset Management sold 7,680 Immunovant shares in Q3 2023, an estimated $146K.
  • Robeco Institutional Asset Management first reported a position in Immunovant in Q1 2023 and held it in 2 quarters.
  • Robeco Institutional Asset Management's Immunovant position peaked at $146K in Q2 2023.
  • 181 funds tracked by Wall St. Rank held Immunovant as of Q3 2023.

Based on Robeco Institutional Asset Management's 13F filing for Q3 2023, filed 24 Oct 2023.